Personalis
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing
Under the non-exclusive deal, Natera will use matched tumor and normal exome sequencing data from Personalis to validate the design of its Signatera ctDNA assays.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.Â
In Brief This Week: Invitae, Exact Sciences, Danaher, and More
Get the latest news from Invitae, Exact Sceicnes, Danaher, SkylineDx, Personalis, and Seegene for the week of 6/28/19.